Characterization of reactions after exclusive transfusion of white cell‐ reduced cellular blood components

Transfusion

Volumn 35, Issue 1, 1995, Pages 20-25

  Dzieczkowski, Jeffery S ^a,c   Barrett, Barbara B ^b   Nester, Deborah A ^b   Campbell, Mary E ^b   Cook, Jane A ^b   Sugrue, Michele W ^b   Andersen, Janet W ^b   Anderson, Kenneth C ^b  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Divisions of Hematologic Malignancies and Biostatistics ^*

^c DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HLA ANTIBODY;

ALLERGY; ALLOIMMUNIZATION; ANTIBODY DETECTION; ARTICLE; BACTERIUM CONTAMINATION; BLOOD COMPONENT THERAPY; BLOOD TRANSFUSION REACTION; FEVER; HUMAN; INCIDENCE;

ANTIBODIES; BLOOD; BLOOD COMPONENT TRANSFUSION; CYTOMEGALOVIRUS INFECTIONS; FILTRATION; HLA ANTIGENS; HUMAN; HYPERSENSITIVITY; INCIDENCE; LEUKAPHERESIS; PLATELETPHERESIS; STAPHYLOCOCCUS EPIDERMIDIS; SUPPORT, U.S. GOV'T, P.H.S.;

EID: 0028872124     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1046/j.1537-2995.1995.35195090654.x     Document Type: Article

References (40)

1. Leukocyte reduction in blood component therapy
2. Use of leucocyte‐poor blood components and HLA‐matched‐platelet donors to prevent HLA alloimmunization
3. Prevention of alloimmunization against platelets
4. Prevention of primary HLA class I allo‐immunization with leucocyte‐poor components produced without the use of platelet filters
5. Prevention of alloimmunization in patients with acute leukemia by use of white cell‐reduced blood components—a randomized trial
6. Use of leukocyte‐depleted platelet concentrates for the prevention of refractoriness and primary HLA alloimmunization: a prospective, randomized trial
7. Prevention of transfusion‐acquired cytomegalovirus infection in infants by blood filtration to remove leucocytes
8. Prevention of primary cytomegalovirus infection in patients with hematologic malignancies by intensive white cell depletion of blood products
9. Use of leukocyte‐depleted platelets and cytomegalovirus‐seronegative red blood cells for prevention of primary cytomegalovirus infection after marrow transplant
10. Brief report: graft‐versus‐host disease associated with transfusion of blood from unrelated HLA‐homozygous donors
11. A case of transfusion‐associated graft‐versus‐host disease not prevented by white cell‐reduction filters
12. The relationship of blood transfusion, tumor staging, and cancer recurrence
13. Transfusion and host defenses against cancer recurrence and infection
14. Perioperative blood transfusion and colorectal cancer recurrence: a qualitative statistical overview and meta‐analysis
15. Allogeneic blood transfusion‐induced enhancement of tumor growth: two animal models showing amelioration by leukodepletion and passive transfer using spleen cells
16. The serology of febrile transfusion reactions
17. The specificity of leukocyte and platelet alloantibodies in sera of patients with nonhemolytic transfusion reactions. Absorption and elution studies
18. The association of febrile transfusion reactions with leuko‐agglutinins
19. Clinical significance of white cell antibodies in febrile nonhemolytic transfusion reactions
20. Febrile transfusion reaction: what blood component should be given next
21. Febrile reactions after platelet transfusion: the effect of single versus multiple donors
22. Preparation and utilization of leukocyte poor apheresis platelets
23. Limited efficacy of leukopoor platelets for prevention of febrile transfusion reactions
24. Cost‐effectiveness of white cell‐reduction filters in treatment of adult acute myelogenous leukemia
25. Clinical use of white cell poor blood components
26. Who should receive leukodepleted blood components
27. The effect of prestorage white cell reduction on the function and viability of stored platelet concentrates
28. Effect of prestorage leukocyte removal on the cytokine levels in stored platelet concentrates
29. Cytokine generation in stored platelet concentrates
30. An animal model of allogeneic donor platelet refractoriness: the effect of the time of leukodepletion
31. Removal of Yersinia enterocolitica from AS‐1 red cells
32. Prevention of growth of Yersinia enterocolitica in blood by polyester fiber filtration
33. Is the febrile response to transfusion due to donor or recipient cytokine? (letter)
34. High circulating interleukin 6 levels associated with acute transfusion reaction: cause or effect? (letter)
35. Large‐volume hemocytometer chamber for accurate counting of white cells (WBCs) in WBC‐reduced platelets: validation and application for quality control of WBC‐reduced platelets prepared by apheresis and filtration
36. Basic microlymphocytotoxity test
37. Strategies for the avoidance of bacterial contamination of blood components
38. Febrile transfusion reactions caused by sensitivity to donor leukocytes and platelets
39. An investigation of non‐hemolytic transfusion reactions